UPDATE: Organovo Responds, Calls Two Reports from Unknown Firms 'Misleading, Inaccurate'

Organovo Holdings, Inc. ONVO, the San Diego-based regenerative medicine company focused on using its breakthrough NovoGen 3D human tissue printing technology to create tissue on demand for medical research and therapeutic applications, today commented on recent reports published by two unaffiliated firms: "Over the past two months, new and unknown firms have issued articles and reports on Organovo, without speaking to Organovo management for information or perspective on Organovo's business or opportunities.  One firm appears to have been formed in February 2014 and has not issued any other reports other than on Organovo; the other firm has a mailing address at a virtual, rent-an-office. "We have had the opportunity to review these reports in detail and can confirm that they contain inaccurate information and that they are exceptionally – and likely intentionally – misleading.  Based on the source of the reports and the blatantly negative tone, we believe they were issued by or at the request of a short seller or short-sellers, who may profit from a decrease in Organovo's stock price following the issuance of these kinds of reports.  "Organovo remains focused on the development of 3D human tissues, including remaining on track for launch of its 3D Liver product in 2014.  The Company believes, based on the feedback from its collaborators and scientific advisors, that the demonstrated performance of the 3D Liver to date provides it with the opportunity to redefine the category of in vitro assays.  The Company's opportunities in in vitro assays include liver, cancer, skin, and kidney tissue markets and in 2013 it signed research collaborations with top corporate and academic partners in three of those areas.  In 2014, Organovo has signed collaboration with the US National Institutes of Health to develop eye tissues and to integrate 3D bioprinting with traditional drug screening technologies. "The Company continues to execute on its plan to drive to near term revenue starting this calendar year.  The Company also is currently in the midst of preclinical development on early bioprinted tissues for direct surgical therapy.  The Company's Board and management team remain focused on these goals, and remain confident in the Company's technology and team."